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ABSTRACT
Objective To investigate secular trends in
echocardiographically determined left ventricular mass
(LVM).
Design, setting and participants Longitudinal
community-based cohort study in Framingham,
Massachussetts. LVM was calculated from routine
echocardiography in 4320 participants (52% women) of
the Framingham offspring cohort at examination cycles
4 (1987–1991), 5 (1991–1995), 6 (1995–1998) and
8 (2005–2008), totalling 13 971 person-observations.
Main outcome measures Sex-speciﬁc trends in
mean LVM (and its components, LV diastolic diameter
(LVDD) and LV wall thickness (LVWT)), and LVM indexed
to body surface area (BSA).
Results In men, age-adjusted LVM modestly
increased from examination 4 to 8 (192 g to 198 g,
p-trend=0.0005), whereas, in women it decreased from
147 g at examination 4 to 140 g at examination 8
(p-trend<0.0001). The trend for increasing LVM in men
tracked with an increasing LVDD (p-trend=0.0002),
whereas the decline in LVM in women was accompanied
by a decrease in LVWT (p-trend<0.0001). Indexing LVM
to BSA abolished the increasing trend in men
(p-trend=0.49), whereas, the decreasing trend in
women was maintained.
Conclusions In our longitudinal analysis of a large
community-based sample spanning two decades, we
observed sex-related differences in trends in LVM, with a
modest increase of LVM in men (likely attributable to
increasing body size), but a decrease in women.
Additional studies are warranted to elucidate the basis
for these sex-related differences.
Left ventricular hypertrophy (LVH) is a major risk
factor for systolic and diastolic heart failure, coron-
ary artery disease, stroke and mortality.1–4 Apart
from age, elevated blood pressure, diabetes and
obesity have been identiﬁed as critical determinants
of increased LV mass (LVM).5 6 Over the last
decades, there have been considerable efforts to
control these risk factors, but epidemiological data
indicate contrasting patterns in prevalence of these
risk factors. For instance, hypertension prevalence
has increased, but at the same time hypertension
control has improved in recent decades in the
USA.7 Obesity prevalence has increased over the
same time period, accompanied by a rising
prevalence of diabetes.8–10 It is unclear if and how
these opposing population trends for key determi-
nants of cardiac mass have inﬂuenced mean LVM
and the prevalence of echocardiographic LVH in
the community. Data from the Framingham Heart
Study from an earlier time period (1950–1989)
indicate that the prevalence of ECG LVH has
decreased markedly over that time period, paral-
leled by and likely related to better control of
hypertension.11 However, these data did not evalu-
ate trends over the more recent decades (1990–
2000s) and were based on electrocardiographic
criteria for LVH; echocardiography is a more sensi-
tive tool for assessing LVM and for ascertaining the
prevalence of LVH.12 Accordingly, we investigated
temporal trends in mean values of LVM mass in a
large community-based cohort that underwent
serial routine echocardiography over the last two
decades and is under continuous surveillance for
development of cardiovascular disease events.
Given that men and women differ in LV size and
morphology, and that known determinants of LV
mass exhibit differential effects in men versus
women,6 we speciﬁcally assessed sex-related differ-
ences in the temporal trends in LVM in our sample.
METHODS
Study sample
The sample comprised participants of the
Framingham Offspring Study.13 Beginning in 1971,
investigators enrolled 5124 individuals into the
offspring cohort who were the children or the
children’s spouses of the participants from the ori-
ginal cohort of the Framingham Heart Study.
Participants in the Framingham offspring cohort
are evaluated approximately every 4–8 years. They
undergo a routine examination at the Heart Study
that includes an extensive cardiovascular history, a
physical examination, blood pressure determin-
ation, anthropometry, a 12-lead ECG, and phlebot-
omy for assessment of cardiovascular disease risk
factors. Body Mass Index (BMI) was deﬁned as
body weight (kg) divided by square of height (m).
Hypertension was deﬁned as blood pressure
≥140/90 or use of antihypertensive medications.14
Diabetes was deﬁned as fasting glucose ≥126 mg/
dL or the use of antidiabetic medications.15
All participants provided written informed
consent at each heart study examination, and the
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study protocols for these examinations were approved by the
institutional review board at the Boston University Medical
Center.
Echocardiography
The current investigation focused on the last two decades when
two-dimensional echocardiography was routinely performed,
that is, examination cycles 4 (1987–1991), 5 (1991–1995), 6
(1996–1998) and 8 (2005–2008). The echocardiographic equip-
ment varied with examinations: Hewlett Packard (model
77020AC) ultrasound machine at examination cycles 4 and 5;
Sonos 1000 Hewlett Packard machine at examination cycle 6
and Sonos 5500 at examination cycle 8. At each of these exami-
nations, two-dimensionally guided M-Mode tracings were
recorded with a minimum of three frames for measuring and
averaging LVM. All echocardiograms were evaluated by an
experienced sonographer or cardiologist using a standardised
reading protocol, with routine implementation of a rigorous
quality control protocol at examination cycles 5 through 8 (see
online supplementary text and table S1 for details). Brieﬂy, we
assessed reproducibility of measurements made by the sonogra-
phers and cardiologist readers over time (between examinations
5 through 8) using a calibration set of echocardiograms (to
assess shifts and drifts in reading), combined with joint reading
sessions and substitition of two-dimensional LV measurements
when M-Mode LV images were inadequate. Readers were not
blinded to sex at any given examination cycle. The end-diastolic
thicknesses of the LV septum and posterior wall thickness, and
LV internal dimensions at the end-diastole LV diastolic diameter
(LVDD) and end-systole were measured using a leading edge to
leading edge technique as recommended by the American
Society of Echocardiography (ASE).16 LVM was calculated
according to ASE guidelines, using the method of Devereux
et al.16 as 0.8(1.04((LV internal dimensions+septal wall thick-
ness+posterior wall thickness)3–(LV internal dimensions)3))
+0.6. The sum of the diastolic thicknesses of the septum and
posterior wall was used as an estimate of LV wall thickness
(LVWT). The reproducibility of echocardiographic measure-
ments was very good, as reported previously17 (see also online
supplementary text and table S1). To account for height and
body weight, we indexed LVM to body surface area (BSA). BSA
was calculated using the DuBois formula as BSA(m)=weight
(kg)0.425 ×Height(cm)0.725×0.007184.18 The presence of
echocardiographic LVH was deﬁned as height-indexed LV mass
>126 g/m in men and >99 g/m in women, respectively, accord-
ing to ASE criteria.19
Statistical analyses
In primary analyses, we included all available echocardiographic
measurements performed in participants aged 30–79 years at
each of the examinations, which yielded 6569 observations in
men (2058 unique individuals) and 7402 in women (2262
unique individuals). However, since myocardial infarction and
heart failure may distort LV geometry (violating assumptions
used for calculating LV mass), we also performed sensitivity ana-
lyses excluding all observations that were obtained from partici-
pants with a history of myocardial infarction or congestive heart
failure at the time of the individual echocardiographic assess-
ment. After exclusion of 561 observations, these analyses were
performed using 6130 echocardiographic measurements in men
(derived from 1925 unique male participants) and 7280 in
women (2239 unique female participants).
Adjusted mean values for LVM, LVDD and LVWTwere calcu-
lated for each examination using sex-speciﬁc linear regression
models with examination cycle as a predictor variable and LVM
as the dependent variable. We assessed two sex-speciﬁc models:
(1) adjusting only for age; and (2) adjusting for age and major
clinical determinants of LVM (excluding height and weight),
namely systolic blood pressure, antihypertensive treatment, dia-
betes mellitus and smoking. These models included covariate
measurements from each examination cycle. Repeated measure-
ments of the same individual were accommodated using
mixed-effects modelling (SAS PROC GLIMMIX) with a com-
pound symmetry covariance matrix. Adjusted means for LVM,
LVDD and LVWTwere compared to the values at examination 4
(referent examination) using Dunnett’s tests, which account for
multiple testing within the assessed group of comparisons.
Additionally, we assessed linear trends across examinations.
Sex-interaction for LVM trends over time was assessed using a
‘three degrees of freedom’ test with examination as a class vari-
able in an age-adjusted model pooling both sexes. Use of a ‘one
degree of freedom’ sex interaction test on the linear trends in
LVM yielded a similar result (p<0.0001).
Age-adjusted ORs for LVH were derived from a logistic
mixed-effects model with a compound symmetry covariance
matrix. In all models, a two-tailed p value of<0.05 was consid-
ered statistically signiﬁcant. All statistical analyses were per-
formed with SAS V.9.2 for Windows.
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manu-
script as written.
RESULTS
Clinical, biochemical and echocardiographic characteristics of
the study sample across examination cycles by sex are listed in
table 1. The (unadjusted) prevalence of echocardiographic LVH
increased across examinations in men but declined in women.
Age-adjusted characteristics are displayed in online
supplementary table S2. In both sexes, age-adjusted systolic and
diastolic blood pressure decreased across examinations and were
paralleled by rising rates of antihypertensive medication use and
declining smoking prevalence. Mean BMI rose across examina-
tions, as did prevalence of diabetes.
Sex-speciﬁc secular trends in mean LV mass and presence of
LV hypertrophy
Age-adjusted mean LVM in men and women at each examination
is shown in table 2. In men, LVM showed a moderate, but signiﬁ-
cant trend of increasing values over time (p=0.0005 for trend),
although mean LVM at examination cycle 5 was slightly lower
compared with that at examination cycle 4 (p<0.0001), which
served as the referent. The age-adjusted OR for echocardio-
graphic LVH at examination 8 (compared with examination 4)
was estimated at 1.41 (95% CI 1.09 to 1.83, p=0.008; ﬁgure 1).
After indexing LVM to body surface, we no longer observed a
consistent trend over time in men (p=0.49 for trend; table 2).
In women, mean age-adjusted LVM decreased modestly across
the examinations with a highly signiﬁcant linear trend
(p<0.0001 for trend), and ﬁndings for LVM indexed to BSA
were very similar (p<0.0001 for trend). The age-adjusted OR
for echocardiographic LVH at examination 8 (compared with
examination 4) was estimated at 0.46 (95% CI 0.37 to 0.57,
p<0.0001; ﬁgure 1).
The observed sex difference in LVM trends was statistically
signiﬁcant (p<0.0001 for interaction test, see Methods for
details). In both sexes, results were maintained in multivariable-
adjusted analyses that incorporated several known correlates of
LVM, and in analyses limited to participants who were free of
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myocardial infarction and heart failure at individual examina-
tions (see online supplementary tables S3 and S4).
Sex-speciﬁc secular trends in LVWT and LV diastolic
diameter
To further elucidate the changes in LV geometry underlying the
observed trends in LV mass, we separately investigated the two
major components of LVM: LVWT and LVDD. The results of
age-adjusted models are also shown in table 2. In men, mean
LVWT did not vary relevantly across examinations. By contrast,
LVDD showed a trend of increasing values across exams
(p=0.0002 for trend), although mean LVDD at exam 5 was
slightly lower than that at referent exam 4 (p<0.0001). In
women, LVWT decreased across examinations (p<0.0001),
whereas a U-shaped relation was observed for LVDD, with
values at examinations 5 and 6 being lower than those at the
referent examination cycle 4 and also compared to examination
cycle 8. Multivariable analyses and analyses restricted to
participants free of myocardial infarction and heart failure
yielded results essentially similar to those observed in
age-adjusted analyses (see online supplementary tables S3
and S4).
DISCUSSION
We analysed temporal trends in echocardiographic LVM and
underlying ventricular geometry in a large, community-based
sample that was followed longitudinally over a two-decade
period (from the late 1980s to the late 2000s). We observed an
intriguing sex-related difference in LVM trends: in men, mean
LVM increased slightly, whereas in women, mean LVM
decreased over time. The trend for increasing LVM in men was
abolished after accounting for BSA, but the decreasing trend in
women was not altered by indexing to BSA. The trend for
increasing LVM in men tracks with increasing LVDD over time,
whereas the trend for decreasing LVM in women appears to be
driven by declining LVWTacross examinations.


















Age, years 52±10 55±10 59±10 65±8 52±10 55±10 59±10 65±8
BMI, kg/m² 27.7±3.9 28.2±4.2 28.6±4.4 29.1±4.8 26.1±5.5 26.8±5.5 27.4±5.7 27.9±6.0
SBP, mm Hg 130±18 129±17 130±17 128±16 125±20 124±20 127±20 127±17
DBP, mm Hg 81±10 77±10 77±9 75±10 77±10 73±10 74±9 73±9
Hypertension, % 42 38 45 63 31 31 38 53
Antihypertensive treatment, % 21 21 31 54 16 18 26 44
Diabetes, % 6.8 9.6 12 20 4.0 5.8 8.2 13
Smoking, % 24 19 15 9 25 20 16 10
Myocardial infarction, % 4.9 5.6 6.4 8 0.7 0.9 1.2 2
Heart failure, % 0.5 0.8 1.5 3 0.3 0.6 0.7 1
ECG-LVH (Sokolow-Lyon)*, % 8 10 7 5 2 2 2 2
LVM, g 188±43 183±38 192±43 202±46 144±30 140±30 140±31 143±32
LVMI, g/m² 95±22 91±19 96±20 99±21 84±16 82±16 80±16 81±16
LVWT, cm 1.99±0.23 2.00±0.25 2.02±0.26 2.07±0.26 1.83±0.20 1.82±0.23 1.82±0.22 1.80±0.22
LVDD, cm 5.10±0.45 4.99±0.41 5.10±0.49 5.13±0.47 4.65±0.40 4.58±0.38 4.56±0.41 4.67±0.39
LVH (ASE)†, % 13 12 22 27 29 25 23 26
Continuous variables summarised by mean±SD, binary variables presented as percentage.
*Defined as a combined voltage of S in V1 or V2 plus R in V5 or V6 ≥3.5 mV.
†Defined by height-standardised LVM ≥126 cm³/m in men and ≥99 cm³/m in women, respectively.
ASE, American Society of Echocardiography; BMI, Body Mass Index; DBP, diastolic blood pressure; ECG-LVH, electrocardiographic left ventricular hypertrophy; LVDD, left ventricular
diastolic diameter; LVM, left ventricular mass; LVMI, LVM indexed to body surface area; LVWT, left ventricular wall thickness; SBP, systolic blood pressure.
Table 2 Age-adjusted time trends in LVM, LVDD and LVWT, stratified by sex
Exam 4 p Exam 5 p (vs exam 4) Exam 6 p (vs exam 4) Exam 8 p (vs exam 4) p for linear trend
Men
LVM, g 192 (1.3) referent 186 (1.1) <0.0001 192 (1.2) 0.99 198 (1.5) 0.005 0.0005
LVMI, g/m² 96 (0.6) referent 93 (0.5) <0.0001 95 (0.5) 0.02 96 (0.7) 0.52 0.49
LVDD, cm 5.09 (0.013) referent 4.99 (0.012) <0.0001 5.11 (0.014) 0.69 5.15 (0.017) 0.02 0.0002
LVWT, cm 2.01 (0.007) referent 2.02 (0.007) 0.38 2.01 (0.007) 0.99 2.03 (0.008) 0.046 0.09
Women
LVM, g 147 (0.8) referent 143 (0.8) <0.0001 140 (0.8) <0.0001 140 (1.0) <0.0001 <0.0001
LVMI, g/m² 86 (0.4) referent 83 (0.4) <0.0001 80 (0.4) <0.0001 78 (0.5) <0.0001 <0.0001
LVDD, cm 4.64 (0.010) referent 4.58 (0.010) <0.0001 4.57 (0.010) <0.0001 4.70 (0.013) 0.001 0.0013
LVWT, cm 1.86 (0.005) referent 1.84 (0.006) 0.053 1.82 (0.005) <0.0001 1.76 (0.007) <0.0001 <0.0001
Data are presented as mean (SE). p Values for comparisons between exams were adjusted for multiple testing by Dunnet-Hsu correction.
LVDD, left ventricular diastolic diameter; LVM, left ventricular mass; LVMI, LVM indexed to body surface area; LVWT, left ventricular wall thickness.
Kaess BM, et al. Heart 2013;99:1693–1698. doi:10.1136/heartjnl-2013-304600 1695
Epidemiology
group.bmj.com on September 6, 2017 - Published by http://heart.bmj.com/Downloaded from 
Trends in LV mass: sex-related differences
An earlier investigation from the Framingham Heart Study eval-
uated electrocardiographic LVH and noted a decreasing preva-
lence during the time period 1950–1989,11 a time frame in
which use of antihypertensive medication rose sharply. In the
present study, we extend these observations into a contemporary
time period using a more sensitive tool for assessing cardiac
mass, namely echocardiography. Interestingly, we demonstrate
disparate trends in both sexes. We can only speculate about the
potential factors underlying these sex-related differences in tem-
poral trends in LVM. The slightly increasing trend in LVM in
men was abolished after indexing LVM to BSA, indicating that
the trend was driven by increasing body size. However, body
size in women increased similarly over time, with no concomi-
tant increase in LVM. It seems plausible that the reduction of
LVM in women may be secondary to improved treatment of
hypertension, a possibility supported by a strong trend for
increasing use of antihypertensive medications across the exami-
nations. However, men in the cohort experienced an equally
dramatic increase in the use of antihypertensive treatment
without an accompanying decrease in LVM. This raises the intri-
guing possibility that women experienced a greater reduction in
LVM with institution of antihypertensive treatment (compared
to men). Several studies have investigated the effect of antihy-
pertensive drugs and demonstrated that treatment with inhibi-
tors of the angiotensin-aldosterone system, as well as β blockers
and other agents, can reduce LV mass, largely independent of
the magnitude of blood pressure lowering.20–23 The SARA study
(eStudio del trAtamiento con candesaRtan en pacientes con
hipertension Arterial según criterios electrocardiográﬁco) noted
that women on antihypertensive treatment experienced greater
LVH regression assessed using Cornell voltage-based ECG cri-
teria (compared to men).24 However, the LIFE study (Losartan
Intervention for Endpoint Reduction in Hypertension) reported
similar reductions in echocardiographic LVM in both sexes.22
Overall, there is no unequivocal evidence establishing sex-
related differences in LVM regression in response to antihyper-
tensive treatment. Nevertheless, limited data suggest that
women are more prone than men to developing concentric
remodelling in response to hypertension,25 and animal models
have conﬁrmed sex-related differences in cardiac remodelling
responses to pressure-overload.26 Also, histologic studies indi-
cate that women may be less prone than men to develop cardio-
myocyte dropout and replacement ﬁbrosis over time, which may
potentially render hypertrophic cardiac tissue in women more
amenable to regression compared to men.27
Another potential explanation of our ﬁndings may be that
women have a better drug compliance (for antihypertensive
treatment) than men. Alternatively, the disparate trends in LVM
in women versus men may be driven by a higher prevalence of
diabetes in men in our sample. Diabetes strongly enhances
age-related LVM growth and reduces beneﬁcial effects of antihy-
pertensive treatment on LVM.6 28 Lastly, it is also possible that
other unidentiﬁed factors may have contributed to the sex-
related differences we observed.
Trends in LV diameter and wall thickness
In our study, the trend for decreasing LVM mass in women
appeared to be driven by a decrease in LVWT, whereas the
mean LV diameter showed no consistent pattern. In the LIFE
trial, a reduction of approximately 2 mm in posterior wall thick-
ness was reported for both the angiotensin receptor blocker and
the β blocker arms, after long-term treatment.22 Hence, our
observed reduction in LVWT of about 1 mm in women may
appear seemingly trivial, but it is well within the range that can
be expected in a partly treated sample. However, the LIFE study
also showed an increase in LVDD with antihypertensive
therapy22 which is not consistently reﬂected in our data. The
slight increase in LVM in men (who experienced similar increase
in antihypertensive agent use) casts further doubt on this
explanation.
LVH: prognostic implications
It is widely accepted that LVH is an adaptive response to
increased afterload, neurohumoral and inﬂammatory stimuli.
Increased LVWT can lead to LV diastolic dysfunction and
decreased perfusion of the inner myocardium. LVM increases
with age.6 In the regression models for our present analyses, an
expected age-related annual increase of 0.55 g in LVM was esti-
mated for women. Hence, our observed age-adjusted decrease in
LVM of 7 g in women from exam 4 to 8 corresponds to a reversal
of approximately 13 years (7/0.55) of cardiac aging. Similarly, in
men, our regression models estimated an expected age-related
annual increase of 0.63 g in LVM. The observed age-adjusted
increase of 6 g from examination 4 to 8, therefore, translates to
almost 10 years (6/0.63) of additional cardiac aging.
Furthermore, in the Framingham Heart Study, presence of
echocardiographic LVH was associated with a more than 50%
increased risk for incident cardiovascular events after adjusting
for standard cardiovascular risk factors.2 Correspondingly,
a recent meta-analysis reported that regression of echocardio-
graphic LVH with hypertension treatment was associated with
an adjusted 46% risk reduction for cardiovascular events.29
Hence, the disparate trends in echocardiographic LVH observed
in men and women in the present investigation may be prognos-
tically important, a premise that warrants further evaluation. Of
note, LVM is an accepted precursor of heart failure, and
Framingham data have reported a trend for decreasing incidence
of heart failure in women (consistent with decrease in mean
LVM in this group), but not in men.30
Strengths and limitations
To our knowledge, the present investigation is the ﬁrst report of
epidemiological trends in echocardiographic LVM in the com-
munity. Our study is based on longitudinal observations of a
pre-enrolled closed cohort, precluding recruitment artefacts in
the observed trends. The design of the Framingham Heart
Study with periodic on-site examinations of participants and
Figure 1 Sex-speciﬁc trends in echocardiographic left ventricular
hypertrophy. Data are ORs with examination cycle 4 as referent. Error
bars represent 95% CIs.
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strict quality-control protocols assure the high quality of echo-
cardiographic and clinical data. Nevertheless, some limitations
of our study should be acknowledged. Due to technical
advances, the ultrasound equipment changed over time, introdu-
cing possibly a source of bias. However, any potential systematic
bias would be expected to similarly affect measurements in men
and women, and hence, is unlikely to explain the disparate
trends observed in the two sexes. Any random error introduced
by the change in equipment would only bias our results towards
the null hypothesis of no change in LVM over time. Another
limitation of our study is the fact that LVH itself is a marker of
morbidity, and hence, participants with LVH may be more likely
to be lost to follow-up. Such a potential bias may lead to a
slight underestimation of mean LVM mass and prevalence of
LVH at the more recent Framingham examinations, but cannot
explain the sex-related differences in LVM trends we observed.
Also, the echocardiographic readers were not blinded to sex at
the examinations; this is unlikely to have inﬂuenced our ﬁndings
across examinations. Additionally, the longitudinal design of our
cohort study implies that pre-enrolled individuals are restricted
to a certain age range and are predominantly Caucasian and of
European descent, and may not adequately represent the
general population. Last, the observational nature of our investi-
gation does not permit any causal inferences to be drawn. In
particular, we cannot directly assess the impact of antihyperten-
sive treatment on LVM.
CONCLUSION
In our longitudinal investigation of a large community-based
cohort, spanning an observation period of two decades during
which routine two-dimensional echocardiography was per-
formed, we observed sex-related differences in trends in LVM,
with a modest increasing trend in men (likely attributable to
increasing body size), and a modest decreasing trend in women.
Additional studies are warranted to replicate our ﬁndings in
independent samples and to further characterise factors that
may contribute to the sex-related differences in trends observed
in our sample.
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